DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A

Information source: Baxalta US Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hemophilia A

Intervention: Octocog alfa (recombinant human coagulation factor VIII) [ADVATE] (Biological)

Phase: Phase 4

Status: Completed

Sponsored by: Baxalta US Inc.

Official(s) and/or principal investigator(s):
Baxter Bio Science Investigator, Study Director, Affiliation: Baxter Healthcare Corporation

Summary

The objective of this clinical study is to compare the pharmacokinetic parameters of 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent with that of 3000 IU Advate using two vials of 1500 IU potency dissolved in 5 mL diluent each (administered in 10 mL diluent in total) in previously treated patients with severe hemophilia A (factor VIII level < 1%).

Clinical Details

Official title: Pharmacokinetic Comparison of 3000 IU Advate (rAHF-PFM) (Using One 3000 IU Potency Vial) With 3000 IU Advate (rAHF PFM) (Using Two 1500 IU Potency Vials) in Previously Treated Patients With Severe Hemophilia A: a Phase 4, Open-label, Prospective, Randomized, Controlled, Crossover, Multiple Center Study

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). Chromogenic Assay

Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). One-stage Activated Partial Thromboplastin Time (aPTT) Assay

Secondary outcome:

Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity (AUC 0-infinity). Chromogenic Assay

Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity (AUC 0-infinity). One-stage aPTT Assay

Incremental Recovery at Cmax - Chromogenic Assay

Incremental Recovery at Cmax - One-stage aPTT Assay

Incremental Recovery at 30 Minutes- Chromogenic Assay

Incremental Recovery at 30 Minutes- One-stage aPTT Assay

Elimination Phase Half-life- Chromogenic Assay

Elimination Phase Half-life- One-stage aPTT Assay

FVIII Clearance- Chromogenic Assay

FVIII Clearance- One-stage aPTT Assay

Mean Residence Time (MRT)- Chromogenic Assay

Mean Residence Time (MRT)- One-stage aPTT Assay

Volume of Distribution at Steady State- Chromogenic Assay

Volume of Distribution at Steady State- One-stage aPTT Assay

Factor VIII (FVIII) Maximum Plasma Concentration (C-max)- Chromogenic Assay

Factor VIII (FVIII) Maximum Plasma Concentration (C-max)- One-stage aPTT Assay

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Participant is 18 to 65 years old, at the time of screening

- Participant has provided signed informed consent

- Participant has severe hemophilia A, defined by a baseline FVIII level < 1% of

normal, as tested at screening at the central laboratory

- Participant's weight is between 55-65 kg

- Participant was previously treated with FVIII concentrate(s) for a minimum of 150

exposure days prior to study entry

- If Participant is HIV positive, he must be immunocompetent as determined with a CD4

count ≥ 200 cells/mm³ (CD4 count at screening)

- Participant is willing and able to comply with the requirements of the protocol

Exclusion Criteria:

- Participant has a detectable FVIII inhibitor at screening, with a titer ≥ 0. 4

Bethesda unit (BU) (Nijmegen modification of the Bethesda Assay) measured at the central laboratory

- Participant has a history of FVIII inhibitors with a titer ≥ 0. 4 BU (by Nijmegen

assay) or ≥ 0. 5 BU (by Bethesda Assay) at any time prior to screening

- Participant has undergone a surgery within 21 days prior to screening or within 6

weeks prior to the anticipated first pharmacokinetics(PK) infusion

- Participant has an abnormal renal function (serum creatinine > 1. 5 mg/dL)

- Participant has active hepatic disease (alanine aminotransferase (ALT) or aspartate

aminotransferase (AST) levels >5 times the upper limit of normal)

- Participant has severe chronic liver disease as evidenced by, but not limited to, any

of the following: International Normalized Ratio (INR) > 1. 4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly, and history of esophageal varices

- Participant has clinical and/or laboratory evidence of abnormal hemostasis from

causes other than hemophilia A (eg, late-stage chronic liver disease, immune thrombocytopenia purpura)

- Participant is currently receiving, or is scheduled to receive during the course of

the clinical study, an immunomodulating drug other than anti-retroviral chemotherapy (eg, alfa-interferon, or corticosteroid agents at a dose equivalent to hydrocortisone greater than 10 mg/day)

- Participant has a known hypersensitivity to mouse or hamster proteins

- Participant has participated in another clinical study involving an investigational

product or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product or investigational device during the course of this clinical study

- Participant is identified by the investigator as being unable or unwilling to

cooperate with study procedures

- Participant is a member of the team conducting this clinical study or is in a

dependent relationship with one of the study team members. Dependent relationships include close relatives (ie, children, partner/spouse, siblings, or parents) as well as employees of the investigator or site personnel conducting the clinical study.

Locations and Contacts

Sofia 1233, Bulgaria

Kirov, Russian Federation

Moscow 125167, Russian Federation

St. Petersburg 195213, Russian Federation

Additional Information

Starting date: June 2009
Last updated: June 26, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017